Various TLR9 agonists based on CpG oligodeoxynucleotides are being tested in animal models of neuroblastoma, cervical carcinoma, and colon cancer [261,280,281,282,283] and in some clinical trials [284]. The gene discussed is TLR9; the disease is cervical carcinoma.